(Reuters) – Swiss generic and biosimilar manufacturer Sandoz on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.
The company said its U.S. subsidiaries had agreed to pay $265 million in a lawsuit with a class of direct drug purchasers, an agreement that does not contain any admission of wrongdoing by the Swiss company.
(Writing by Bartosz Dabrowski in Gdansk; Editing by Miranda Murray)
